Astellas Pharma Global Development, Inc.: Phase 3 study completed, 7 enrolled (Neurogenic Detrusor Overactivity)
Astellas Pharma Global Development, Inc.: Phase 3 study completed, 7 enrolled (Neurogenic Detrusor Overactivity). Its enrollment of 7 is below the median of 80 (1st percentile). Dated 34 days ago, it serves as a historical benchmark. Score 65/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 7 · 1th percentile of 8,879 ClinicalTrialStartPulse records · 0.1x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Astellas Pharma Global Development, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity |
| NCT ID | NCT05621616 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Neurogenic Detrusor Overactivity |
| Intervention types | drug |
| Target enrollment | 7 |
| Site countries | Philippines, Poland |
| Posted | 2022-11-18 |
| Planned start | 2024-02-28 |
| Event | Completed |
| Event date | 2026-09-17 |
| Last update posted | 2026-10-01 |
| enrollment percentile | 1th of 8,879 (median 80, 0.1x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Astellas Pharma Global Development, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Astellas Pharma Global Development + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-01
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Astellas Pharma Global Development, Inc. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Astellas Pharma Global Development, Inc.'s enrollment: 1st percentile of 8,879 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
65 / 100 Score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
What is the ClinicalTrialStartPulse record for Astellas Pharma Global Development, Inc.?
Astellas Pharma Global Development, Inc.'s Phase 3 study (NCT05621616) in Neurogenic Detrusor Overactivity, first posted 2022-11-18: completed (2026-09-17), in an update posted 2026-10-01.
How does Astellas Pharma Global Development, Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 7 is below the median (1th percentile); smaller records often move faster and face less competition. It is 34 days old, still within a typical 45-day follow-up window.
Astellas Pharma Global Development, Inc. vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Astellas Pharma Global Development, Inc. | NONUS | 7 | 1st | 2026-10-01 |
| Janssen-Cilag Ltd. | US | 120 | 65th | 2026-11-03 |
| NervGen Pharma | US | 150 | 71st | 2026-11-03 |
| Janssen Research & Development, LLC | US | 159 | 72nd | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 3 ClinicalTrialStartPulse: Outside the US only
How to monitor Astellas Pharma Global Development, Inc. and peer phase 3 records
Get new ClinicalTrialStartPulse records like Astellas Pharma Global Development, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.